Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
about
Nonmedical use of prescription medications in young adultsMarketed New Drug Delivery Systems for Opioid Agonists/Antagonists Administration: A Rapid OverviewAssessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records.Prescription opioid misuse and its relation to injection drug use and hepatitis C virus infection: protocol for a systematic review and meta-analysis.The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.A practical and ethical solution to the opioid scheduling conundrum.Oxycodone combined with opioid receptor antagonists: efficacy and safety.The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response.Drug Formulation Advances in Extended-Release Medications for Pain Control.Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers.Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.Oxycodone extended release capsules for the treatment of chronic pain.Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting.[Misuse of opioid analgesics. An internet analysis].Designing a tool allowing for a standardized assessment of resistance to drug diversion.Comments and Suggestions from Pain Specialists Regarding the CDC's Proposed Opioid Guidelines.Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain.
P2860
Q26862505-F8614D8F-278D-466E-B9D0-EDDBC274FAD9Q28079382-0F53DBA6-4BB5-42CD-9016-4D3C2108A5FBQ31154136-8336B977-9C31-4DF5-ABE5-95F66CE51683Q34153684-8D50402C-6E81-449A-966B-C74131910ECEQ34530594-6A64F53A-BD85-4092-B4D5-07706516FB9CQ37390980-ABB9E4B9-9A8E-450D-9C17-17B974C6D431Q38093671-5D72EF8D-607E-4088-95F3-D15503CD83E1Q38533533-3675D3DB-084B-4F40-B7A5-860AAE78B4C8Q38809652-0A95ECC2-92A6-4E0F-A7A2-60DF0E8F5A72Q38830845-CC3E7511-B636-455A-B3AE-CA2C662643E0Q38851461-B627DDB4-AF4E-469D-87B3-BE049ACC4CF7Q38917891-5B68A383-2E26-4F0E-BAF7-53B8FEE7025AQ39157561-6E1564ED-C52F-4B97-A2FD-387821F3689DQ39202730-1D9AE58E-D0EB-44E3-8D2F-907D2278C1E5Q43317466-4A37B150-069C-4ECE-9733-F812A21C7E7CQ43576588-5179A2D2-7613-4B9B-A973-DE7AC478FE92Q44340245-B26724EA-D8C5-498F-8D5D-DF32BCC3149EQ52603231-E43E6CDB-A869-4ABB-AA49-2D7FA7B7BF5C
P2860
Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@ast
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@en
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@nl
type
label
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@ast
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@en
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@nl
prefLabel
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@ast
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@en
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@nl
P2860
P1433
P1476
Will abuse-deterrent formulati ...... ul in achieving their purpose?
@en
P2093
Bernard Bannwarth
P2860
P304
P356
10.2165/11635860-000000000-00000
P577
2012-09-01T00:00:00Z
P6179
1040756595